Significance of the Higher Molar Dose of Aflibercept 8 mg

Opinion
Video

Panelists discuss how the aflibercept 8 mg higher molecular concentration enables extended durability through increased VEGF binding capacity and longer intraocular drug levels, potentially allowing for less frequent dosing while maintaining efficacy.

Video content above is prompted by the following:

  • Aflibercept 8 mg was recently approved for treating age-related macular degeneration and diabetic macular edema. Could you discuss the significance of the higher molar dose?

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
2 experts in this video
3 experts are featured in this series.
Related Content
Zeteo Biomedical receives new EU and US patents for its drug delivery technologies

Zeteo Biomedical receives new EU and US patents for its drug delivery technologies

Kassi Filkins
June 11th 2025
Article

ZTech-L and ZTech-P, as part of the ZTech portfolio, supports administering therapeutics in both liquid and dry powder formulations

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A bridge made from building blocks has an incomplete area. A hand reaches down with the missing block to close the gap. Concept image for age-related macular degeneration therapy and treatment article, IOL implantation and ophthalmology. Image credit: ©patpitchaya – stock.adobe.com

An implantable option bridges the gap for patients with AMD

Federico Badalà, MD
June 4th 2025
Article

Long-term benefits and vision preservation using an extended macular vision IOL

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Two business people in suits shake hands in front of a European Union flag. Concept image for Optegra and EssilorLuxottica acquisition, European expansion, expand into new areas of medical technology. Image credit: ©New Africa – stock.adobe.com

EssilorLuxottica acquires Optegra clinics with support from MidEuropa

Hattie Hayes
May 30th 2025
Article

The Optegra platform currently operates in the Czech Republic, the Netherlands, Poland, Slovakia and the United Kingdom

A pharmacist helps a customer access medication. Concept image for neovascular age-related macular degeneration eye drop treatment therapy. Image credit: ©Gorodenkoff – stock.adobe.com

Topline results from investigational nAMD drop SYL1801 (Sylentis)

Kassi Filkins
May 19th 2025
Article

Three dose level cohorts of the small interfering RNA therapeutic were evaluated in a double-blind study

© 2025 MJH Life Sciences

All rights reserved.